MODERNA INC. news, videos and press releases
For more news please use our advanced search feature.
MODERNA INC. - More news...
MODERNA INC. - More news...
- Moderna to Present at Upcoming Conferences in December 2024
- Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
- Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
- Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Moderna to Present at Upcoming Conferences in November 2024
- Moderna Named a Top Employer by Science for Tenth Consecutive Year
- Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
- Abbas Hussain Joins Moderna's Board of Directors
- Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
- Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
- Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
- Moderna R&D Day Highlights Progress and Strategic Priorities
- Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
- EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
- Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
- Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
- Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
- Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
- Moderna to Host Investor Event - R&D Day and Business Updates
- Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
- Moderna and Coursera Launch Free Course on mRNA Technology
- Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
- David Rubenstein Joins Moderna's Board of Directors
- Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
- Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines
- Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
- EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
- Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
- Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
- Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
